Communications medicine最新文献

{"title":"Implementing health economics for pharmacogenomics research translation in Africa.","authors":"Mohamed Zahir Alimohamed, George Dennis Obeng, Marcell Csanadi, Collen Masimirembwa, Collet Dandara","doi":"10.1038/s43856-025-00955-y","DOIUrl":"10.1038/s43856-025-00955-y","url":null,"abstract":"<p><p>Pharmacogenomics studies how a person's inherited genes influence response to therapeutic drugs. Many drugs do not work in all patients and pharmacogenomics can assist in the identification of patients who are better suited to particular drugs or patients who need adjusted drug doses to reach better treatment outcomes. This stratification of patients could be beneficial in Africa as it would allow drugs that would ordinarily be discontinued due to toxicity on a proportion of the populations to be used in a directed manner in people for whom it is not toxic. However, there has been limited use of pharmacogenomics. One of the key issues has been the need to demonstrate the economic benefits of adopting pharmacogenomics implementation and the impact on healthcare cost drivers. Integration of pharmacogenomics into clinical practice has huge potential in Africa due to the large genetic diversity in African populations. This Perspective article explores the current pharmacogenomics landscape, the health economics associated with its implementation, and future directions for pharmacogenomics research translation in Africa.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"241"},"PeriodicalIF":5.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.","authors":"Carla Martín Pérez, Anna Ramírez-Morros, Alfons Jiménez, Marta Vidal, Edwards Pradenas, Diana Barrios, Mar Canyelles, Rocío Rubio, Inocencia Cuamba, Luis Izquierdo, Pere Santamaria, Benjamin Trinité, Josep Vidal-Alaball, Luis M Molinos-Albert, Julià Blanco, Ruth Aguilar, Anna Ruiz-Comellas, Gemma Moncunill, Carlota Dobaño","doi":"10.1038/s43856-025-00943-2","DOIUrl":"10.1038/s43856-025-00943-2","url":null,"abstract":"<p><strong>Background: </strong>The ongoing evolution of SARS-CoV-2, particularly through the emergence of new variants, continues to challenge our understanding of immune protection. While antibody levels correlate with protection against earlier variants such as Alpha and Delta, their relationship with Omicron sub-variants remains unclear.</p><p><strong>Methods: </strong>To investigate the role of antibody levels and neutralizing activity in preventing breakthrough infections, we analyzed longitudinal SARS-CoV-2 humoral responses and neutralizing activity against the ancestral virus and major emerging variants in a well-characterized cohort of healthcare workers in Spain (N = 405).</p><p><strong>Results: </strong>We find that antibody levels and neutralization titers are key indicators of protection against SARS-CoV-2, including the more evasive BQ.1 and XBB Omicron variants. Higher IgG and IgA levels are associated with protection over three 6-month follow-up periods sequentially dominated by BA.1, BA.2, BA.5, BQ.1, and XBB Omicron sub-variants, although the strength of the association between antibody levels and protection declines over time.</p><p><strong>Conclusions: </strong>Our findings demonstrate that binding antibody levels and neutralizing responses are valid correlates of protection against more evasive BQ.1 and XBB Omicron variants, although the strength of this association diminishes over time. Additionally, our results underscore the importance of continuous monitoring and updating vaccination strategies to maintain effective protection against emerging SARS-CoV-2 variants.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"243"},"PeriodicalIF":5.4,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends of blood-based markers in various psychiatric disorders and their cross-sectional brain structure associations.","authors":"Yu-Jia Wang, Zairen Zhou, Yu-Zhu Li, Ju-Jiao Kang, Jin-Tai Yu, Jian-Feng Feng, Wei Cheng, Guoqing Pan, Jia You, Linbo Wang","doi":"10.1038/s43856-025-00957-w","DOIUrl":"10.1038/s43856-025-00957-w","url":null,"abstract":"<p><strong>Background: </strong>Understanding the temporal trends of blood-based biomarkers and their associations with brain structure is crucial for early detection and intervention in psychiatric disorders. This study aimed to explore these trends in the decade before and after diagnosis, along with the cross-sectional relationships with brain structures.</p><p><strong>Methods: </strong>Utilizing UK Biobank data, we conducted a nested case-control analysis of individuals aged 40-69 years diagnosed with anxiety (n = 27,216), bipolar disorder (n = 1325), depression (n = 36,570), or schizophrenia (n = 1478) within 10 years of baseline. We used multivariable linear regression to analyze temporal trends and brain structure associations for 31 blood cell counts, 28 biochemistry markers, and 168 serum metabolites.</p><p><strong>Results: </strong>Here we show that compared to controls, significant temporal divergence is observed in 39, 6, 55, and 12 blood-based markers for anxiety, bipolar disorder, depression, and schizophrenia, respectively. Common biomarkers like cystatin C, red blood cells, hemoglobin, hematocrit, and total bilirubin are identified. Biomarkers cluster into groups with either linear or non-linear trends. Among the linearly changing biomarkers, some have a widening difference from controls while others have a narrowing one. For example, in the case of depression, HDL-TG demonstrates an increasing disparity over time, while cholesterol exhibits a decreasing trend. Non-linear clusters often show reversals around diagnosis, indicating potential treatment effects. Differential associations are found between biomarkers and brain regions, including the orbitofrontal cortex, hippocampus, and accumbens.</p><p><strong>Conclusions: </strong>This study reveals the temporal trends of blood-based biomarkers in psychiatric disorders and their correlations with brain structure, aiding early detection and potentially enhancing clinical outcomes.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"239"},"PeriodicalIF":5.4,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical manifestations of sickle cell disease in Africa and its association with foetal haemoglobin parameters.","authors":"Evans Xorse Amuzu, Florence Urio, Elliot Eli Dogbe, Peter Ponsian, Suraj Yawnumah Abubakar, Chinedu Okeke, Olasinbo Olumuyiwa Balogun, Petronilla Jean Ozumba, Alex Osei-Akoto, Vivian Paintsil, Obiageli Nnodu, Emmanuel Balandya, Julie Makani, Madu Anazoeze, Daniel Ansong, Siana Nkya","doi":"10.1038/s43856-025-00954-z","DOIUrl":"10.1038/s43856-025-00954-z","url":null,"abstract":"<p><strong>Background: </strong>Prevalence of sickle cell disease (SCD) across African countries ranges between 1-3% and contributes up to 7-16% of under-five mortality. In order to bridge the gap in management and cognate research, the SickleInAfrica consortium was established in 2017 to facilitate collaboration among African nations in order to establish regionally relevant healthcare standards for SCD patients. This work utilised the SickleInAfrica platform to study the levels of HbF and F cells and their relationship with sickle cell disease clinical manifestations in Ghana, Nigeria and Tanzania.</p><p><strong>Methods: </strong>This study enrolled 290 individuals with SCD aged five years and above who were confirmed to be at steady state and were hydroxyurea naïve. Clinical history was obtained using an interviewer-administered questionnaire. Haematological parameters were determined by an automated haematology analyser, while quantification of HbF and F cells was implemented by high-performance liquid chromatography and flow cytometry, respectively. Age-adjusted logistic regression was employed to assess the association of HbF with the clinical manifestations.</p><p><strong>Results: </strong>The most reported complication of SCD, requiring management in a hospital setting is pain crises, ranging from 66-96% with the highest in Tanzania and lowest in Ghana. HbF and F cell parameters show significant association with transfusion rates, frequency of painful crises and episodes of febrile illness.</p><p><strong>Conclusion: </strong>This work highlights important differences and similarities across SCD populations in the three countries. This is important especially in development of interventions in the light of personalised medicine.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"238"},"PeriodicalIF":5.4,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining frailty index thresholds for older people across multiple countries in sub-Saharan Africa.","authors":"Gideon Dzando, Paul R Ward, Lillian Mwanri, Richard K Moussa, Justice Moses K Aheto, Rachel C Ambagtsheer","doi":"10.1038/s43856-025-00952-1","DOIUrl":"10.1038/s43856-025-00952-1","url":null,"abstract":"<p><strong>Background: </strong>Despite the increasing attention on frailty as a global public health concern, frailty screening among older people in Sub-Saharan Africa (SSA) continues to rely on instruments and thresholds from high-income countries. These instruments and thresholds may not be useful in SSA due to contextual differences. We explored the development of a frailty threshold for older people in SSA.</p><p><strong>Methods: </strong>We utilized pooled cross-sectional data from four SSA countries (Kenya, Ghana, Uganda and Côte d'Ivoire) to determine a frailty index threshold for 5527 older people (50 years and above) using a two-step approach. The mean ages of the participants ranged from 62.13 (SD: 9.60) to 74.00 (SD: 9.40) years. The participants were mostly females across the four countries, ranging from 50.1% in Côte d'Ivoire to 65.3% in Kenya. Country-specific frailty thresholds were developed using the Receiver Operating Characteristics (ROC) method. The primary thresholds were further combined into a single threshold using random effects meta-analysis. Subgroup analyses and meta-regression were conducted to explore potential sources of heterogeneity in the pooled frailty threshold.</p><p><strong>Results: </strong>Here we show the Area Under the Curves from the ROC analyses ranging between 0.91 (CI: 0.89, 0.93) and 0.94 (CI: 0.92, 0.97), with sensitivities ranging from 0.83 to 0.94 and specificities from 0.72 to 0.87. An overall threshold of 0.29 (95% CI: 0.25, 0.33) was obtained after pooled analysis of the country-specific thresholds.</p><p><strong>Conclusions: </strong>This work demonstrates that using context-specific data can yield valuable insights into frailty thresholds among older people in SSA, enabling more culturally relevant interventions. Effective frailty screening must account for population-level differences, including demographic, health, and socio-cultural factors.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"237"},"PeriodicalIF":5.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between grammar and schizophrenia: a systematic review and meta-analysis.","authors":"Dalia Elleuch, Yinhan Chen, Qiang Luo, Lena Palaniyappan","doi":"10.1038/s43856-025-00944-1","DOIUrl":"10.1038/s43856-025-00944-1","url":null,"abstract":"<p><strong>Background: </strong>Schizophrenia significantly impairs everyday communication, affecting education and employment. Such communication difficulties may arise from deficits in syntax-understanding and generating grammatical structures. Research on syntactic impairments in schizophrenia is underpowered, with inconsistent findings, and it is unclear if deficits are specific to certain patient subgroups, regardless of symptom profiles, age, sex, or illness severity.</p><p><strong>Methods: </strong>A pre-registered (Open Science Framework: https://doi.org/10.17605/OSF.IO/7FZUC ) search using PubMed, Scopus, PsycINFO, and Web of Science databases up to May 1, 2024, for all studies investigating syntax comprehension and production in schizophrenia vs. healthy controls. Excluding studies on those <18 years of age and qualitative research, we extracted Cohen's d and log coefficient of variation ratio and used Bayesian meta-analysis across 6 domains: 2 in comprehension and 4 in production in patient-control comparisons. Study quality was evaluated using a modified Newcastle-Ottawa Scale, with moderators (age, sex, study quality, language) tested via meta-regression.</p><p><strong>Results: </strong>We identify 86 relevant articles, of which 45 have sufficient data for meta-analysis (n = 2960 participants, 64.4% English, weighted mean age(sd) = 32.3(5.6)). Bayesian meta-analysis shows strong evidence of syntactic deficits in schizophrenia across all domains (d = 0.65-1.01, overall random-effects d = 0.86, 95% CrI [0.67-1.03]), with syntax comprehension being most affected, with weak publication bias. People with schizophrenia show increased variability in comprehension and production of long and complex utterances (lnCVR = 0.21, 95% CrI [0.07-0.36]), hinting at subgroups with differing performance.</p><p><strong>Conclusions: </strong>Robust impairments in grammatical comprehension and production in schizophrenia suggest opportunities for targeted interventions focusing on syntax, a rule-based feature amenable to cognitive, educational, and linguistic interventions.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"235"},"PeriodicalIF":5.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis.","authors":"Andreas Hagen Røssevold, Xavier Tekpli, Ole Christian Lingjærde, Hege G Russnes, Johan Vallon-Christersson, Elin Borgen, Jon Lømo, Øystein Garred, Esmaeil Dorraji, Vessela N Kristensen, Bjørn Naume, Jon Amund Kyte","doi":"10.1038/s43856-025-00865-z","DOIUrl":"10.1038/s43856-025-00865-z","url":null,"abstract":"<p><strong>Background: </strong>Tumor immune cell infiltration is a favorable prognostic factor in triple-negative breast cancer. Most triple-negative tumors belong to the aggressive basal-like subtype. We hypothesized that immune gene expression may identify low-risk patients for whom adjuvant chemotherapy can be de-escalated.</p><p><strong>Methods: </strong>The expression of 753 immune-related genes was analyzed in tumor biopsies from 45 patients with basal-like disease and no lymph node metastases (Oslo1 cohort) and evaluated for prognostic value. Findings were validated in two independent cohorts. Oslo1 biopsies were also analyzed for tumor-infiltrating lymphocytes (TIL) and tertiary lymphoid structures (TLS).</p><p><strong>Results: </strong>Here we show that a high expression of CTLA4 (above 63^rd percentile) is associated with an excellent prognosis in the Oslo1 cohort. None of the patients in the CTLA4^high group suffered disease recurrence (median follow-up 7.4 years) or breast cancer-related death (median follow-up 17.7 years). Analysis of the SCAN-B (n = 233; 97% without distant recurrence in CTLA4^high group) and METABRIC cohorts (n = 155; 93% disease-specific survival in CTLA4^high group) validates this finding, which also applies to patients who did not receive chemotherapy. CTLA4 expression correlates with TIL score and TLS levels (Oslo1 cohort), but no TIL^low/CTLA4^high patients died from breast cancer, suggesting that the CTLA4 readout identifies low-risk patients not captured by TIL assessment.</p><p><strong>Conclusions: </strong>A high primary tumor expression of CTLA4 identifies patients with an excellent prognosis, for whom standard chemotherapy may be de-escalated or omitted.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"234"},"PeriodicalIF":5.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort.","authors":"Anastasiya Yudina, Cagdas Tazearslan, Artur Baisangurov, Ekaterina Nuzhdina, Kelley Lauziere, Vitaly Segodin, Svetlana Podsvirova, Sergey Starikov, Madison Chasse, Kirill Shaposhnikov, Leznath Kaneunyenye, Olesia Klimchuk, Natalia Kuzkina, Noel English, Gleb Khegai, Danielle Sookiasian, Daria Shafranskaya, Dawn Fernandez, Yaroslav Lozinsky, Andrew Sobolev, Mary Abdou, Polina Turova, Konstantin Chernyshov, Alexey Efremov, Samuel Andrewes, Aviva Feinberg, Brianna McKenna, Jessica H Brown, Anna Love, John Curran, Jochen Lennerz, Alexander Bagaev","doi":"10.1038/s43856-025-00934-3","DOIUrl":"10.1038/s43856-025-00934-3","url":null,"abstract":"<p><strong>Background: </strong>Combining RNA sequencing (RNA-seq) with whole exome sequencing (WES) from a single tumor sample can substantially improve the detection of clinically relevant alterations in cancer. However, routine clinical adoption of this integrated approach remains limited, especially for RNA-seq, due to the absence of standardized validation frameworks.</p><p><strong>Methods: </strong>We developed and validated an assay that integrates RNA-seq and WES for evaluating gene expression, gene fusions, tumor microenvironment signatures, somatic single nucleotide variants (SNVs), insertions/deletions (INDELs), and copy number variations (CNVs). Exome-wide somatic reference standards were generated to support analytical validation using multiple sequencing runs of cell lines at varying purities.</p><p><strong>Results: </strong>Assay validation involves 3 steps: (1) analytical validation using custom reference samples containing 3042 SNVs and 47,466 CNVs; (2) orthogonal testing in patient samples; and (3) assessment of clinical utility in real-world cases. Applied to 2230 clinical tumor samples, the integrated assay enables direct correlation of somatic alterations with gene expression, recovery of variants missed by DNA-only testing, and improves detection of gene fusions. In addition to uncovering clinically actionable alterations in 98% of cases, the assay also reveals complex genomic rearrangements that would likely have remained undetected without RNA data.</p><p><strong>Conclusions: </strong>This study provides practical validation guidelines for integrated RNA and DNA sequencing in clinical oncology. The combined assay enhances the detection of actionable alterations, thereby facilitating personalized treatment strategies for cancer patients.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"236"},"PeriodicalIF":5.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Correction: Proteomics approach identifies aqueous humor biomarkers in retinal diseases.","authors":"Kevin Huang, Cheryl Schofield, Trung Nguy, Randall Dere, Vincent Wolowski, Juliane Siebourg-Polster, Andreas Dieckmann, Justus G Garweg, Michael Chang, Lee Honigberg, Jason Hackney, Vahan B Indjeian","doi":"10.1038/s43856-025-00940-5","DOIUrl":"10.1038/s43856-025-00940-5","url":null,"abstract":"","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"233"},"PeriodicalIF":5.4,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body composition after treatment of intra-mucosal gastric cancer with endoscopic resection compared to gastrectomy.","authors":"Hae Young Kim, Won Chang, Sungsoo Lee, Jungheum Cho, So Hyun Kang, Yoon Jin Lee, Young Hoon Kim","doi":"10.1038/s43856-025-00931-6","DOIUrl":"10.1038/s43856-025-00931-6","url":null,"abstract":"<p><strong>Background: </strong>Patients who undergo gastrectomy may experience changes in their body composition, which may in turn affect survival. However, whether endoscopic resection differs from gastrectomy in its effect on body composition remains unclear.</p><p><strong>Methods: </strong>This retrospective study included 2267 patients who received either gastrectomy or endoscopic resection for intramucosal gastric cancer. Transverse images at the L3 vertebra level of the patient's staging and follow-up CTs were segmented for the measurement of fat and skeletal muscle areas. In 1134 patients who were propensity score-matched, as well as in all 2267 patients, gastrectomy vs. endoscopic resection was compared in terms of the percentage change in skeletal muscle, visceral fat, subcutaneous fat, and the proportion of newly developed sarcopenia.</p><p><strong>Results: </strong>Changes in skeletal muscle, visceral fat, and subcutaneous fat are all greater following gastrectomy (p value < 0.001 for all). The change in skeletal muscle is -2.9 % (-3.4%, 2.3%) and 0.3% (-0.2%, 0.8%) following gastrectomy and endoscopic resection, respectively. The change in visceral fat is -50.2 % (-54.1%, -46.3%) and 8.6% (1.7%, 15.6%), respectively. The change in subcutaneous fat is -26.5% (-30.4%, -22.5%) and 3.9% (-0.3%, 8.0%), respectively. The proportion of newly developed sarcopenia is also higher following gastrectomy (1.9% vs. 3.4%), although the difference was not significant. The results are also consistently observed for all patients, regardless of propensity score-matching.</p><p><strong>Conclusions: </strong>Change in body composition is greater after gastrectomy than after endoscopic resection. Such knowledge may contribute to refining the criteria for treatment selection between gastrectomy and endoscopic resection in patients with intra-mucosal gastric cancer.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"231"},"PeriodicalIF":5.4,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}